Abstract
INTRODUCTION
Alzheimer’s disease (AD) is now diagnosed biologically. Since subjective cognitive decline (SCD) may indicate preclinical AD, assessing AD-biomarkers is crucial. We investigated cognitive and neurodegenerative trajectories in SCD over 24 months based on biomarker positivity, and evaluated the predictive value of plasma biomarkers.
METHODS
The CoSCo prospective cohort included older adults with SCD. Participants were categorized into high- and low-risk groups based on plasma biomarkers (amyloid beta [Aβ] 42/40, phosphorylated tau 181 [p-tau181], and glial fibrillary acidic protein [GFAP]), and magnetic resonance imaging (MRI) findings to compare outcomes.
RESULTS
High-risk SCDs (n = 23, 23%) revealed greater decline in general cognition, memory recall, frontal function, and hippocampal volumes compared to low-risk SCDs. Combined scores of plasma and MRIs yielded the best predictions compared with other biomarker categories.
DISCUSSION
SCD participants with high-risk experience faster cognitive and neurodegenerative declines. A combination of plasma biomarkers and MRIs could be used for screening and prognosis.
Highlights
This is part of a multicenter prospective cohort study in Korea.
We investigated cognitive and atrophic trajectories in SCD over 24 months.
High risk SCDs revealed greater cognitive decline and hippocampal atrophy.
Integration of plasma and MRIs yielded better predictions than other categories.
Risk stratification using plasma and MRIs can be used for screening and prognosis.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Yun Jeong Hong,
Seong Hye Choi,
SangYun Kim,
Jee Hyang Jeong,
Kee Hyung Park,
Min Jeong Wang,
Sungmin Kang,
Dong Won Yang,
CoSCo study group | December 29, 2024